US Patent

US7815942 — Rasagiline formulations of improved content uniformity

Method of Use · Assigned to Teva Pharmaceutical Industries Ltd · Expires 2027-08-27 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pharmaceutical preparations of R(+)-N-propargyl-1-aminoindan salts, including RASAGILINE MESYLATE, with enhanced content uniformity.

USPTO Abstract

Disclosed are pharmaceutical preparations of R(+)-N-propargyl-1-aminoindan salts having enhanced content uniformity, processes for preparation of the compositions, and their uses.

Drugs covered by this patent

rasagiline-mesylate (RASAGILINE MESYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-219`	—	rasagiline-mesylate
`U-219`	—	rasagiline-mesylate

Patent Metadata

Patent number: US7815942
Jurisdiction: US
Classification: Method of Use
Expires: 2027-08-27
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Teva Pharmaceutical Industries Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.